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F-18 FDG (2-[18-F] fluoro-2-deoxy-D-glucose) is the most frequently used radiopharmaceutical for 
PET and PET CT imaging exams. The FDA recently approved the use of the PTSTM (Portable Test 
System) as an alternative to the standard test proposed by the United States Pharmacopeia using the 
LAL (Limulus Amebocyte Lysates), that takes longer to perform (about 1h) than the PTSTM (15 min). 
Recent studies have demonstrated that radiation could interfere with the PTSTM test. In order to study 
the effects of radiation on the PTSTM test and/or equipment, 27 batches of F-18 FDG produced in the 
Nuclear Engineering Institute were analyzed. The results showed that no direct correlation with radiation 
was found in any of the cases. 
Uniterms: 18-FDG/utilization. Radiopharmaceuticals. Nuclear medicine. Endotoxin test. Portable Test 
System/radiation effects
O FDG-18 é o radiofármaco mais utilizado nos exames de PET e PET CT. O FDA recentemente aprovou 
o uso do PTSTM (Portable Test System) como método alternativo ao teste padrão de endotoxina, proposto 
pela Farmacopéia Americana, considerando que no primeiro há um tempo de espera de 1 hora frente a 
somente 15 minutos do segundo. Estudo recentes demonstram que a radiação poderia interferir no teste 
do PTSTM. De modo a avaliar os efeitos da radiação no teste PTSTM foram analisados 27 lotes de F-18 
FDG produzidos no Instituto de Engenharia Nuclear. Os resultados demonstraram que em todos os casos 
nenhuma correlação direta com a radiação foi observada.
Unitermos: FDG-18/utilização. Radiofármacos. Medicina nuclear. Teste de endotoxina. Portable Test 
System/efeitos da radiação.
INTRODUCTION
Radioisotopes are used in nuclear medicine for 
diagnostic and therapeutic purposes. Radiopharmaceu-
ticals may be used in oncology at the initial stage, to 
assess response to treatment, residual disease, recurrent 
diagnosis or restaging. Another field of study involving 
radiopharmaceuticals is that of large vessel vasculitis, 
granulomatous diseases and dementia (Santos-Oliveira, 
Carneiro-Leão, Smith, 2008).
The word pyrogen, which can be traced to the Greek 
pyro, meaning burning or fire and gennaó meaning to make 
or to create, is now used as an apt description for subs-
tances that produce elevated body temperature. Pyrogens 
are usually bacterial products and remains, or decaying 
products of bacterial cell walls. Even at minimum doses, 
these substances induce elevated body temperature when 
injected into humans and animals. Pyrogens are usually 
high-molecular-weight substances of a polymerous nature, 
akin to lipopolysaccharids. Pyrogens can be either micro-
bial or non-microbial. Endotoxins are high-molecular-
weight complexes associated with the outer membrane 
of gram-negative bacteria (GNB). They are the most 
usual cause of the elevated body temperature, induced by 
contaminated drug products. Their pyrogenic activity is 
higher than that of other pyrogenic substances. It could 
be said that the absence of such bacterial endotoxins in a 
drug implies the absence of pyrogenic components in the 
studied drug in general. Endotoxins are similar to lipo-
polysaccharids, they are heat stable and can survive the 
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sterilization process (Blechová, Pivodová, 2001).
The use of LAL for endotoxin detection stemmed 
from Bang’s observation that the infection of Limulus 
polyphemus, the horseshoe crab, induced by GNB, results 
in extensive intravascular clotting and death. Levin and 
Bang later demonstrated that the extracellular coagulation 
of Limulus hemolymph (blood) was caused by a reaction 
between endoxin and a coagulative protein in amebocytes, 
circulating in Limulus hemolymph (Levin, Bang 1964). In 
a subsequent study, Levin et al. developed a sensitive assay 
for endotoxin in human plasma using the material lysed 
from Limulus amebocytes (Levin, Tomasulo, Oser, 1970). 
Young, Levin and Prendergast then isolated, purified and 
described the LAL coagulative protein and proved that the 
reaction between lysate and endotoxin is of an enzymatic 
nature (Young , Levin, Prenderagst, 1993).
Limulus Amebocyte Lysate (LAL) is a lyophilized 
preparation made from the amebocytes of the horseshoe 
crab Limulus polyphenus. The LAL will clot to form 
a gel in the presence of endotoxin from gram-negative 
microorganisms. Since the LAL test method is far more 
rapid than the USP (United States Pharmacopoeia) rabbit 
pyrogen test method, it has been used as a preferable test 
(Watchel, Tsuji, 1977). Nevertheless, despite being more 
rapid than the rabbit test method, the LAL test is still slow, 
especially for radiopharmaceuticals.
The PTSTM (Portable Test SystemTM) is a novel 
endotoxin assay in which dry LAL-reagents are fixed to 
a cartridge and results are interpolated from an archived 
standard curve by a validated chromogenic assay. The use 
of the of PTS has become an alternative to the traditional 
USP test using LAL due the shorter time taken to complete 
the whole process, about 15 minutes against 1 hour for the 
traditional test (FDA, 1987; Zijlstra et al., 1997; Fukumori 
et al., 2007)
However, studies by Hung, Iverson, Jacobson and 
Mahoney (2005) demonstrated that special care is ne-
cessary when using the PTS with radiopharmaceuticals, 
since during the test the FDG can inhibit gel formation. 
Therefore, in order to prove this theory an experimental 
study with 27 samples of 18-FDG produced in the Nuclear 
Engineering Institute was conducted. 
METHODOLOGY
The assays were performed using the EndosafeÒ 
PTSTM equipment and the kit for the test (cartridge) from 
the Charles River LaboratoriesTM . The methodology adop-
ted was that described in the equipment manual (25mL of 
F-18 FDG injectable solution were fixed in the cartridge 
and then the equipment run). The samples used were 27 
successive daily batches of F-18 FDG produced routinely 
in the Nuclear Engineering Institute. No dilution factors 
were used. 
RESULTS AND DISCUSSION
The PTSTM works with a dry LAL reagent and uses 
validated interpolated internal values. Among the parame-
ters revealed by the PTSTM test, the most important is the 
recovery percentage. Briefly, the recovery rate shows the 
ability of the sample to react with the dry LAL reagents 
and form the chromogenic compound. According to the 
manufacturer of the PTSTM, a good range for the recovery 
parameter is between 50% and 200%. Values above or 
below this range mean that the reaction between the sam-
TABLE I - Activity and correlation with other parameters
RHP/
Sample
Dilution 
Factor
PTSTM 
Result 
(EU/ml)
 PTSTM 
Recovery 
test
Activity 
(mCi)
FDG-18/1 1 <0.050 74 477.0
FDG-18/2 1 <0.050 15 960.0
FDG-18/3 1 <0.050 104 811.0
FDG-18/4 1 0.056 90 923.0
FDG-18/5 1 0.118 146 972.0
FDG-18/6 1 0,164 102 972.0
FDG-18/7 1 <0.050 94 772.0
FDG-18/8 1 <0.050 110 865.0
FDG-18/9 1 <0.050 92 865.0
FDG-18/10 1 <0.050 76 846.0
FDG-18/11 1 <0.050 38 902.0
FDG-18/12 1 <0.050 57 852.0
FDG-18/13 1 <0.050 40 751.0
FDG-18/14 1 <0.050 52 530.0
FDG-18/15 1 <0.050 74 701.0
FDG-18/16 1 <0.050 62 630.0
FDG-18/17 1 <0.050 47 505.0
FDG-18/18 1 <0.050 58 739.0
FDG-18/19 1 <0.050 58 652.0
FDG-18/20 1 <0.050 80 800.0
FDG-18/21 1 <0.050 27 1006.0
FDG-18/22 1 <0.050 95 1080.0
FDG-18/23 1 <0.050 44 1149.0
FDG-18/24 1 <0.050 58 1108.0
FDG-18/25 1 <0.050 36 1075.0
FDG-18/26 1 <0.050 100 1298.0
FDG-18/27 1 <0.050 47 1826.0
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ple and the reagents of the kit was not good and that the 
results are not reliable.
Samples 4, 5, 6, are the most representative cases. 
Variations were detected in the PTSTM test in all these sam-
ples, as shown in Table 1. However the values found are 
under the acceptable limit (0.25EU/mL). Thus, although 
they are different from the others this does not mean they 
are not good enough. Relatively to recovery parameter 
no single observation is possible. The same occurs with 
the activity, since they are too similar and the results are 
too different.
In the case of samples 2, 11, 13, 17, 21 and 23, the 
recovery range value given by the PTSTM was lower than 
the acceptable limit (50 to 200%), but the endotoxin limit 
was acceptable at less than 0.050 EU/mL. Although the 
samples had been approved for the assay, the recovery 
value is an important parameter linked to the reliability of 
the results. This means that in a case where the samples 
have to be re-analyzed the new results found can differ to 
the original results. Again, no relationship with activity, 
recovery test and endotoxin limit is possible. The range 
of each parameter is too high to try to create a hypothesis.
The attempt to correlate all the problems described 
previously with the radiation of the sample failed, as 
shown in Table1. Samples 24, 25, 26 and 27 are the most 
representative. The four samples have the highest values of 
activity. However, the value of recovery varies without any 
correlation. For samples where the recovery of the PTSTM 
test was in the range (50-200%), no relationship with 
the radiation level was ascertained since no relationship 
among the values was found.
It is important to note that all these samples were 
analyzed by the traditional method described in the USP 
and no clots were formed in any of the cases. This implies 
that according to the traditional methods all the samples 
were approved.
CONCLUSION
The PTS was shown to be a good alternative en-
dotoxin test, especially for radiopharmaceuticals, where 
time is one of the most important parameters during the 
routine assay. The results were able to corroborate the use 
of PTSTM in the daily routine for 18-FDG. However, se-
veral points must be evaluated in more depth, particularly 
recovery range.
Although the results shown above demonstrated 
no relationship between radiation and the endotoxin test 
using the PTSTM further studies are needed for other radio-
pharmaceuticals, in particular radiopharmaceuticals based 
on Iodine since iodine has coloration when in solution 
and could interfere with the test through the formation of 
color-complexes.
Therefore, we recommend that before introducing 
PTS in the daily routine for radiopharmaceuticals, further 
validations should be conducted.
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